Featured Research

from universities, journals, and other organizations

Heat-Shock Vaccine Stops Bacteria Dead

Date:
March 16, 1999
Source:
Weizmann Institute
Summary:
Autoimmunity, in which the body attacks its own tissues, has traditionally been viewed as spelling nothing but trouble. But now Weizmann Institute scientists have shown that it's possible to "enlist" an autoimmune mechanism for a beneficial cause -- fighting outside intruders such as bacteria. This new approach may lead to the development of improved vaccines for preventing various infectious diseases and possibly for treating cancerous tumors.

Autoimmunity, in which the body attacks its own tissues, has traditionally been viewed as spelling nothing but trouble. But now Weizmann Institute scientists have shown that it's possible to "enlist" an autoimmune mechanism for a beneficial cause -- fighting outside intruders such as bacteria. This new approach may lead to the development of improved vaccines for preventing various infectious diseases and possibly for treating cancerous tumors.

The emergence of drug-resistant bacteria and the growing concern over the appearance of intractable infections have recently brought new urgency to the search for improved vaccines. A vaccine's job is to trigger the production of antibodies against an infectious agent. Ideally, the antibodies should be high-performance, that is, quick to appear, long-lasting and capable of improving themselves with time. Such antibodies can only be created if they are produced with the assistance of the immune system's T-helper cells, which provide their help once they spot the infectious agent. Unfortunately, many infectious organisms camouflage themselves in a sugary coat so that the T cells can't see them. In such cases, the antibodies that are produced are of lower quality and less effective fighters against disease.

To outwit the camouflaged bacteria, scientists have begun to resort to a sophisticated approach: when designing improved vaccines, they attach vaccine molecules to "carrier" proteins that stimulate T cells and enlist them in the antibody production process. However, until now these carrier proteins have had a major drawback: in most cases, they came from diphtheria and tetanus bacteria and, as a result, they tended to trigger the production of antibodies against themselves, a process which interferes with the creation of the antibodies needed to prevent the disease.

This is where the Weizmann Institute's new concept comes in. Prof. Irun Cohen of the Immunology Department had the clever idea of replacing the diphtheria- and tetanus-derived carriers with heat-shock proteins, so called because they are produced by the body in response to stress situations. People are born with a natural immunity to these proteins, which are known to stimulate T-helper cells.

"Heat-shock proteins are perfect enhancers of the T-helper cell response,but because they are part of autoimmunity -- the body's reaction against its own components -- no one thought of redirecting their activity to fight an external threat such as infection," Cohen says. He conducted the study, reported in February in the Journal of Infectious Diseases, with Prof. Mati Fridkin and with Drs. Stephanie Konen-Waisman and Avi Cohen.

The scientists immunized mice with a vaccine composed of a heat-shock protein carrier attached to the sugar-coat molecule of a dangerous pneumococcal bacterium. The immunized mice were then infected with lethal doses of the bacteria. Ordinarily, 2-3 bacteria of this type suffice to kill an unprotected mouse within a day or two. In the study, the heat-shock-protein vaccine offered nearly complete protection against a bacterial army of several million. This protection was a thousand times greater than that provided by a commercial pneumococcal vaccine, which only succeeded in partially fighting off an infection of 1,000 pneumococcal bacteria.

The Weizmann team now plans to test the effectiveness of the new approach -- patented through Yeda Research and Development Co., the Institute's technology transfer arm -- for vaccinations against tuberculosis and viral infections. The scientists are also considering a vaccine for use in cancer therapy, in which the immune system would be activated to attack tumor cells, thus preventing their spread.

Prof. Cohen holds the Helen and Morris Mauerberger Chair in Immunology and heads both the Weizmann's Robert Koch Minerva Center for Research in Autoimmune Diseases and the Center for the Study of Emerging Diseases in Jerusalem. Prof. Fridkin holds the Lester B. Pearson Chair of Protein Research. The study was partially funded by Peptor Ltd. and a Center of Excellence grant from the Israel Science Foundation.


Story Source:

The above story is based on materials provided by Weizmann Institute. Note: Materials may be edited for content and length.


Cite This Page:

Weizmann Institute. "Heat-Shock Vaccine Stops Bacteria Dead." ScienceDaily. ScienceDaily, 16 March 1999. <www.sciencedaily.com/releases/1999/03/990316063431.htm>.
Weizmann Institute. (1999, March 16). Heat-Shock Vaccine Stops Bacteria Dead. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/03/990316063431.htm
Weizmann Institute. "Heat-Shock Vaccine Stops Bacteria Dead." ScienceDaily. www.sciencedaily.com/releases/1999/03/990316063431.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins